The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma

Rambam Health Care Campus

Status: Withdrawn

Conditions: Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse

Study type: Observational

Funder types: Other

Identifiers

NCT00498667

cc-NHL2615_CTIL

Details and patient eligibility

About

A retrospective analysis will be performed regarding the usefulness of PET/CT performed following 2 cycle of chemotherapy in evaluation of progression, free survival and overall survival of patients with aggressive non Hodgkin Lymphoma.

Full description

Patients who were treated for aggressive non-Hodgkin lymphoma with adriamycin containing regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of chemotherapy to rule out disease progression . Currently a retrospective evaluation of PET/CT as a predictive value for progression free survival and overall survival is evaluated

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• aggressive non-Hodgkin lymphoma b cells
• age 18-70
• bilirubin less then 2
• creatinine less then 2
• Pet/CT performed post 2 cycles

Exclusion criteria

• no PET/CT post 2 cycles performed
• bilirubin >2
• creatinine more then 2
• HIV positivity

Trial design

0 participants in 1 patient group

PET/CT

Description:

all patients with aggressive lymphoma who had a baseline and interim pet/ct study